LSKB Still Upbeat On Rivoceranib Despite ANGEL Failure In Late-Line Gastric Cancer

 
• By Jung Won Shin
  
Closed up finger on keyboard with word CLINICAL TRIALS
Rivoceranib Faces Delay After Primary Endpoint Failure • Source: Shutterstock

More from Clinical Trials

More from R&D